152 related articles for article (PubMed ID: 9516863)
1. Screening for neuroblastoma is ineffective in reducing the incidence of unfavourable advanced stage disease in older children.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B; Brodeur GM
Eur J Cancer; 1997 Oct; 33(12):2106-12. PubMed ID: 9516863
[TBL] [Abstract][Full Text] [Related]
2. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
3. Screening for neuroblastoma in North America. Preliminary results of a pathology review from the Quebec Project.
Takeuchi LA; Hachitanda Y; Woods WG; Tuchman M; Lemieux B; Brisson L; Bernstein M; Brossard J; Leclerc JM; Byrne TD
Cancer; 1995 Dec; 76(11):2363-71. PubMed ID: 8635044
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
[TBL] [Abstract][Full Text] [Related]
5. Screening of infants and mortality due to neuroblastoma.
Woods WG; Gao RN; Shuster JJ; Robison LL; Bernstein M; Weitzman S; Bunin G; Levy I; Brossard J; Dougherty G; Tuchman M; Lemieux B
N Engl J Med; 2002 Apr; 346(14):1041-6. PubMed ID: 11932470
[TBL] [Abstract][Full Text] [Related]
6. Screening for neuroblastoma in North America. 2-year results from the Quebec Project.
Woods WG; Tuchman M; Bernstein ML; Leclerc JM; Brisson L; Look T; Brodeur GM; Shimada H; Hann HL; Robison LL
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):312-9. PubMed ID: 1456396
[TBL] [Abstract][Full Text] [Related]
7. Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project.
Tuchman M; Lemieux B; Auray-Blais C; Robison LL; Giguere R; McCann MT; Woods WG
Pediatrics; 1990 Nov; 86(5):765-73. PubMed ID: 2152340
[TBL] [Abstract][Full Text] [Related]
8. Incidence of neuroblastoma after a screening program.
Barrette S; Bernstein ML; Robison LL; Samson Y; Brossard J; Weitzman S; Woods WG
J Clin Oncol; 2007 Nov; 25(31):4929-32. PubMed ID: 17971590
[TBL] [Abstract][Full Text] [Related]
9. Pathology review of screening negative neuroblastomas: a report from the Quebec Neuroblastoma Screening Project.
Kawakami T; Monobe Y; Monforte H; Woods WG; Tuchman M; Lemieux B; Brisson L; Bernstein M; Brossard J; Leclerc JM; Byrne TD; Triche TJ; Shimada H
Cancer; 1998 Aug; 83(3):575-81. PubMed ID: 9690552
[TBL] [Abstract][Full Text] [Related]
10. Biological aspects of neuroblastomas identified by mass screening in Quebec.
Brodeur GM; Look AT; Shimada H; Hamilton VM; Maris JM; Hann HW; Leclerc JM; Bernstein M; Brisson LC; Brossard J; Lemieux B; Tuchman M; Woods WG
Med Pediatr Oncol; 2001 Jan; 36(1):157-9. PubMed ID: 11464873
[TBL] [Abstract][Full Text] [Related]
11. Screening for neuroblastoma: a review of the evidence.
Chamberlain J
J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
[TBL] [Abstract][Full Text] [Related]
12. A population-based study of neuroblastoma incidence, survival, and mortality in North America.
Bernstein ML; Leclerc JM; Bunin G; Brisson L; Robison L; Shuster J; Byrne T; Gregory D; Hill G; Dougherty G
J Clin Oncol; 1992 Feb; 10(2):323-9. PubMed ID: 1732433
[TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma mass screening: the arguments for and against.
Treuner J; Schilling FH
Eur J Cancer; 1995; 31A(4):565-8. PubMed ID: 7576969
[TBL] [Abstract][Full Text] [Related]
14. Poor prognosis neuroblastoma: is screening the answer?
Craft AW; Parker L
Br J Cancer Suppl; 1992 Aug; 18():S96-101. PubMed ID: 1503935
[TBL] [Abstract][Full Text] [Related]
15. Compliance in a screening program for neuroblastoma.
Campion P; Woods WG; Lemieux B
Prev Med; 1998; 27(4):590-6. PubMed ID: 9672953
[TBL] [Abstract][Full Text] [Related]
16. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan.
Yamamoto K; Hayashi Y; Hanada R; Kikuchi A; Ichikawa M; Tanimura M; Yoshioka S
J Clin Oncol; 1995 Aug; 13(8):2033-8. PubMed ID: 7636545
[TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma: an enigmatic disease.
Brossard J; Bernstein ML; Lemieux B
Br Med Bull; 1996 Oct; 52(4):787-801. PubMed ID: 9039732
[TBL] [Abstract][Full Text] [Related]
18. Is neuroblastoma screening evaluation needed and feasible?
Estève J; Parker L; Roy P; Herrmann F; Duffy S; Frappaz D; Lasset C; Hill C; Sancho-Garnier H; Michaelis J
Br J Cancer; 1995 Jun; 71(6):1125-31. PubMed ID: 7779698
[TBL] [Abstract][Full Text] [Related]
19. Effects of mass screening on age-specific incidence of neuroblastoma.
Bessho F
Int J Cancer; 1996 Aug; 67(4):520-2. PubMed ID: 8759611
[TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma of the urinary bladder, preclinically detected by mass screening.
Yokoyama S; Hirakawa H; Ueno S; Yabe H; Hiraoka N
Pediatrics; 1999 May; 103(5):e67. PubMed ID: 10224211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
